2022
Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK+ NSCLC in ALTA-1L.
Camidge D, Kim H, Ahn M, Yang J, Han J, Hochmair M, Lee K, Delmonte A, Campelo R, Kim D, Griesinger F, Felip E, Califano R, Spira A, Thomas M, Gettinger S, Tiseo M, Liu Y, Zhang P, Popat S. Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK+ NSCLC in ALTA-1L. Journal Of Clinical Oncology 2022, 40: 9072-9072. DOI: 10.1200/jco.2022.40.16_suppl.9072.Peer-Reviewed Original ResearchBlinded independent review committeeTarget lesion assessmentTarget lesion responseLesion shrinkageLesion responseLesion assessmentCochran-Armitage trend analysisRandomized phase 3 trialShrinkage groupPhase 3 trialDepth of responseIndependent review committeeLonger median timeMajority of ptsAssociation of depthRECIST v1.1PFS eventsMedian ageOS ratesMedian timeStudy endTarget lesionsLower riskDeep responsesBrigatinibAngiographic Lesion Discordance in Women Presenting With Ischemic Heart Disease: Comparison of Visual Assessment, Quantitative Coronary Angiography, and Quantitative Flow Ratio.
Gitto M, Saito Y, Taoutel R, Schneider MD, Papoutsidakis N, Ardito S, Henry G, Cristea E, Lansky AJ, Altin SE. Angiographic Lesion Discordance in Women Presenting With Ischemic Heart Disease: Comparison of Visual Assessment, Quantitative Coronary Angiography, and Quantitative Flow Ratio. Journal Of Invasive Cardiology 2022, 34: e202-e209. PMID: 35089162, DOI: 10.25270/jic/21.00146.Peer-Reviewed Original ResearchConceptsQuantitative coronary angiographyIschemic heart diseaseQuantitative flow ratioStress perfusion imagingDiameter stenosisCoronary angiographyIschemic symptomsCoronary revascularizationHeart diseasePerfusion imagingStenosis severityIndependent core laboratoryCohort of womenVisual assessmentCoronary stenosis severityConsecutive patientsAngiographic severityCoronary stenosisLesion assessmentClinical practiceCore laboratoryLesionsAngiographyWomenBlinded operators
2020
Response criteria for intratumoral immunotherapy in solid tumors: ItRECIST.
Goldmacher G, Khilnani A, Andtbacka R, Luke J, Hodi F, Marabelle A, Harrington K, Perrone A, Tse A, Madoff D, Schwartz L. Response criteria for intratumoral immunotherapy in solid tumors: ItRECIST. Journal Of Clinical Oncology 2020, 38: 3141-3141. DOI: 10.1200/jco.2020.38.15_suppl.3141.Peer-Reviewed Original ResearchLesion responseResponse assessmentIntratumoral immunotherapySolid tumorsTarget lesion responseModification of therapyResponse Evaluation CriteriaRoutine clinical practiceOverall response assessmentUnique treatment strategyInjected lesionsIT drugsRECIST 1.1Immunotherapy trialsNew lesionsTumor burdenMetastatic melanomaTrial protocolClinical trialsInitial progressionTreatment strategiesTherapeutic modalitiesLesion assessmentNadir valuesTreatment evolves
2016
3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival
Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Zhao Y, Hamm B, Gebauer B, Lin M, Geschwind JF, Chapiro J. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. European Radiology 2016, 26: 3243-3252. PMID: 26762942, PMCID: PMC4942412, DOI: 10.1007/s00330-015-4168-3.Peer-Reviewed Original ResearchConceptsHazard ratioOverall survivalTransarterial chemoembolizationBaseline MRIHepatocellular carcinomaTumor burdenDominant lesionTumor assessmentTumor volumeMultivariate cox proportional hazard ratiosCox proportional hazard ratiosCurrent radiological methodMethodsThis retrospective analysisProportional hazard ratiosBCLC staging systemKaplan-Meier plotsTumor diameterPatient survivalStaging systemHCC patientsMultiple lesionsLiver volumeRetrospective analysisLesion assessmentPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply